Mirum Pharmaceuticals Crushes Q1 2025 Earnings
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Mirum Pharmaceuticals soars in Q1 2025 with a 61% revenue surge, reaching $111.6M, and raises full-year guidance to $435-450M. Key approvals for CTEXLI, LIVMARLI, and a single-tablet LIVMARLI version boost sales. LIVMARLI alone hits $73.2M globally, up 70%. The commercial teams execution enhances patient access, and analysts praise strong market positioning. The pipeline advances with Volixibats VISTAS trial wrapping enrollment and VANTAGE showing durable pruritus relief. Cash stands at $298.6M, with positive operating cash flow and improving margins. Mirum is poised to lead in the rare disease space with these achievements.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/346e3a15c7a9db70